服用苏比利/缬沙坦治疗期间中区域肾上腺素原的变化

IF 16.9 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

European Journal of Heart Failure Pub Date : 2023-07-04 DOI:10.1002/ejhf.2957

Peder L. Myhre, Yuxi Liu, Ian J. Kulac, Brian L. Claggett, Margaret F. Prescott, G. Michael Felker, Javed Butler, Ileana L. Pi?a, Jean L. Rouleau, Michael R. Zile, John J.V. McMurray, Jonathan H. Ward, Scott D. Solomon, James L. Januzzi

引用次数: 1

摘要

目的肾上腺髓质素是一种血管舒张肽，在微循环和内皮稳态中起作用。肾上腺髓质素是neprilysin的底物，因此可能在sacubitril/缬沙坦(Sac/Val)治疗的有益效果中发挥作用。方法和结果对156例采用Sac/Val治疗的心力衰竭伴射血分数降低(HFrEF)患者和264例采用Sac/Val或缬沙坦治疗的保留射血分数(HFpEF)患者进行了中部促肾上腺髓质素(MR-proADM)检测。超声心动图和堪萨斯城心肌病问卷调查结果在基线和HFrEF队列6个月和12个月后收集。HFrEF组MR-proADM的中位(Q1-Q3)基线浓度为0.80 (0.59-0.99)nmol/L, HFpEF组为0.88 (0.68-1.20)nmol/L。在Sac/Val治疗12周后，MR-proADM在HFrEF中位数增加49%，在HFpEF中位数增加60%，而在缬沙坦治疗的患者中没有显著变化(中位数为2%)。MR-proADM的增加与较高的Sac/Val剂量相关。MR-proADM的变化与n端前b型利钠肽、心肌肌钙蛋白T和尿环鸟苷单磷酸的变化呈弱相关。MR-proADM升高与血压降低相关，但与超声心动图参数或健康状况变化无显著相关性。结论:与缬沙坦治疗相比，Sac/Val治疗后MR-proAD浓度显著升高。neprilysin抑制引起的MR-proADM变化与心脏结构、功能或健康状况的改善无关。关于肾上腺髓质素及其相关肽在心力衰竭治疗中的作用，需要更多的数据。临床试验注册:PROVE-HF ClinicalTrials.gov标识符:NCT02887183, PARAMOUNT ClinicalTrials.gov标识符:NCT00887588。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Changes in mid-regional pro-adrenomedullin during treatment with sacubitril/valsartan

Adrenomedullin is a vasodilatory peptide with a role in microcirculatory and endothelial homeostasis. Adrenomedullin is a substrate for neprilysin and may therefore play a role in beneficial effects of sacubitril/valsartan (Sac/Val) treatment.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European Journal of Heart Failure 医学-心血管系统

CiteScore

27.30

自引率

11.50%

发文量

365

审稿时长

1 months

期刊介绍： European Journal of Heart Failure is an international journal dedicated to advancing knowledge in the field of heart failure management. The journal publishes reviews and editorials aimed at improving understanding, prevention, investigation, and treatment of heart failure. It covers various disciplines such as molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, clinical sciences, social sciences, and population sciences. The journal welcomes submissions of manuscripts on basic, clinical, and population sciences, as well as original contributions on nursing, care of the elderly, primary care, health economics, and other related specialist fields. It is published monthly and has a readership that includes cardiologists, emergency room physicians, intensivists, internists, general physicians, cardiac nurses, diabetologists, epidemiologists, basic scientists focusing on cardiovascular research, and those working in rehabilitation. The journal is abstracted and indexed in various databases such as Academic Search, Embase, MEDLINE/PubMed, and Science Citation Index.